Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab.

Hasan Ahmad Albitar, Yahya Almodallal, Rick Nishimura, Vivek N Iyer

Open access · goldAbstract readCase Reports

In one paragraph

Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 96% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hasan Ahmad AlbitarDepartment of Internal Medicine, Mayo Clinic, Rochester, MN.

Yahya AlmodallalDepartment of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN.

Rick NishimuraDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Vivek N IyerDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.

Mayo Clinic in Arizona · USMayo Clinic · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia-related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients receiving intravenous bevacizumab therapy for severe hereditary hemorrhagic telangiectasia-related bleeding who were found to have abnormal mobile masses on the mitral valve (n=2) and aortic valve (n=1). The clinical impact of these findings is unknown and requires further study.

Indexed as

CI, cardiac indexGI, gastrointestinal tractHHT, hereditary hemorrhagic telangiectasiaHOCF, high-output cardiac failureIV, intravenousLAAC, left atrial appendage closureTTE, transthoracic echocardiography

Identifiers

PMID32793873

DOI10.1016/j.mayocpiqo.2020.01.002

PMCPMC7411168

OpenAlexW3022034079

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.